Notice of Results

RNS Number : 6139K
LungLife AI, INC
03 September 2021
 

 

LungLife AI, Inc.
(the "Company" or "LungLife")

 

Notice of Results

Investor Presentation

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that its maiden unaudited half-year report for the six months ended 30 June 2021 will be announced on Thursday 9 September 2021.

 

Investor presentation

Paul Pagano, Chief Executive Officer, and David Anderson, Chief Financial Officer, will be hosting a live online presentation relating to the half-year report via the Investor Meet Company platform at 4.30pm (BST) on Thursday 9 September 2021. The presentation is open to all existing and potential shareholders.

 

Investors can sign up to Investor Meet Company for free and register for the presentation here:

https://www.investormeetcompany.com/lunglife-ai-inc/register-investor  

 

Investors who already follow LungLife on the Investor Meet Company platform will automatically be invited.

 

Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the "Ask a Question" function.  Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.

 

 

For further information please contact:

 

LungLife AI, Inc.

www.lunglifeai.com

Paul Pagano, CEO 

Via Walbrook PR

David Anderson, CFO

 



Investec Bank plc (Nominated Adviser & Broker)

Tel: +44 (0)20 7597 5970

Daniel Adams / Virginia Bull / Cameron MacRitchie

 


 

Walbrook PR Limited

 Tel: +44 (0)20 7933 8780 or  LungLifeAI@walbrookpr.com

Paul McManus / Alice Woodings

Mob: 07980 541 893 / 07407 804 654

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORSSLFUEEFSEIU
UK 100

Latest directors dealings